Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide Doxorubicin Vincristine and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

摘要

PURPOSEIbrutinib has shown activity in non–germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non–germinal center B-cell DLBCL.